As illustrated above, multiple targets TKIs inhibit angiogenesis by disturbing the signaling transduction of VEGFR or PDGFR, while ICBs target tumor-infiltrating CD8+ T cells and reverse the immune exhaustion state, both of which modulate TME of RCC instead of tumor epithelium. This evidence concerns the gene CD8A and neoplasm.